Herpes Simplex - Pipeline Insight, 2024

Herpes Simplex - Pipeline Insight, 2024

DelveInsight’s, “Herpes Simplex – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Herpes Simplex pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Herpes Simplex Understanding

Herpes Simplex: Overview

Infection with herpes simplex virus, commonly known as herpes, can be due to either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2). HSV-1 is mainly transmitted by oral-to-oral contact to cause infection in or around the mouth (oral herpes). However, HSV-1 can also be transmitted through oral-genital contact to cause infection in or around the genital area ( genital herpes). HSV-2 is almost exclusively transmitted through genital-to-genital contact during sex, causing infection in the genital or anal area (genital herpes). Symptoms of oral herpes include painful blisters or open sores called ulcers in or around the mouth. Sores on the lips are commonly referred to as “cold sores.” Genital herpes caused by HSV-1 can be asymptomatic or can have mild symptoms that go unrecognized. When symptoms do occur, genital herpes is characterised by 1 one or more genital or anal blisters or ulcers. Antiviral medications, such as acyclovir, famciclovir, and valacyclovir, are the most effective medications available for people infected with HSV. These can help to reduce the severity and frequency of symptoms, but cannot cure the infection.

""Herpes Simplex - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes Simplex pipeline landscape is provided which includes the disease overview and Herpes Simplex treatment guidelines. The assessment part of the report embraces, in depth Herpes Simplex commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes Simplex collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Herpes Simplex R&D. The therapies under development are focused on novel approaches to treat/improve Herpes Simplex.

Herpes Simplex Emerging Drugs Chapters

This segment of the Herpes Simplex report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Herpes Simplex Emerging Drugs

• Pritelivir: AiCuris

Pritelivir is a highly potent inhibitor of HSV replication. It belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is being developed for the treatment of acyclovir-resistant and dual-resistant (resistant to acyclovir and intolerant or resistant to foscarnet) infections in immune-compromised patients. It has received the US FDA Breakthrough Therapy Designation. AiCuris Anti-infective Cures AG has begun Phase III development of its lead compound pritelivir, a novel helicase-primase inhibitor, for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.

• UB-621: United BioPharma

UB-621 is a first-in-class anti-gD mAb (UB-621) with demonstrated strong viral suppression of transmission and recurrence of HSV1 and HSV2, developed over ten years of research collaboration between the University of Washington, the National Institute for Allergy and Infectious Diseases, University of Duisburg Essen, Germany, and Dartmouth College. In October 2021 United BioPharma announced that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic. Together with United BioPharma, the two institutions will test the effectiveness of UB-621, a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2) in preparation for phase II trials in the United States and China.

Further product details are provided in the report……..

Herpes Simplex: Therapeutic Assessment

This segment of the report provides insights about the different Herpes Simplex drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Herpes Simplex

There are approx. 15+ key companies which are developing the therapies for Herpes Simplex. The companies which have their Herpes Simplex drug candidates in the most advanced stage, i.e. Phase III include, AiCuris.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Herpes Simplex pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Herpes Simplex: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Herpes Simplex therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes Simplex drugs.

Herpes Simplex Report Insights

• Herpes Simplex Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Herpes Simplex Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Herpes Simplex drugs?
• How many Herpes Simplex drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes Simplex?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Herpes Simplex therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Herpes Simplex and their status?
• What are the key designations that have been granted to the emerging drugs?